Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, the company's holding subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”) received approval from the State Drug Administration to conduct phase II/III adaptive seamless design clinical trials for FXS5626 tablets (original project code: AC-201, “FXS5626” for short) to treat non-segmental vitiligo. Fosun Pharmaceutical Industry plans to carry out clinical research on this drug in China when conditions are met.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.